Joëlle A Pasman

May 21, 2024 | medrxiv.org | Joëlle A Pasman |Jacob Bergstedt |Arvid Harder |Ying Xiong

PFS is consultant and shareholder at Neumora Therapeutics. No other authors report potential conflicts of interest. This work was supported by the US National Institutes of Mental Health (R01MH123724), the European Unions Horizon 2020 Research and Innovation Programme (CoMorMent project; Grant #847776) and the European Research Council (grant agreement ID 101042183). The OSMR analyses have been conducted using the UK Biobank Resource under Application Number 22224.

Mar 27, 2023 | thelancet.com | Joëlle A Pasman |Joeri J. Meijsen |Marit Haram

SummaryBackgroundMajor depressive disorder (MDD) is a common psychiatric disorder associated with a high disease burden. This study gives a comprehensive overview of the prevalence, outcomes, treatment, and genetic epidemiology of MDD within and across the Scandinavian countries. MethodsThis study has aimed to assess and compare across Norway, Denmark, and Sweden 1) the prevalence and trajectories of MDD and comorbidity, 2) outcomes and treatment, and 3) heritability (Denmark and Sweden only).